Achieve Life Sciences, Inc.
ACHVNasdaqCIK 949858HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Operating income and Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPS−$0.80Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.80 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure−116.2% on a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q3 FY20242024-09-30 | Q4 FY20242024-12-31 | Q1 FY20252025-03-31 | Q2 FY20252025-06-30 | Q3 FY20252025-09-30 | Q4 FY20252025-12-31 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (0.36)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure | not reported (Diluted EPS not reported) | (0.37)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure | (0.37)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure | (0.28)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-268074.Report this figure | not reported (Diluted EPS not reported) | (0.19)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-218177.Report this figure | (0.80)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344624.Report this figure | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (4.08)Diluted EPS, FY2021, twelve months to 2021-12-31−$4.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-28, accession 0000950170-24-038049.Report this figure | (4.00)Diluted EPS, FY2022, twelve months to 2022-12-31−$4.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-11, accession 0000950170-25-036831.Report this figure | (1.50)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure | (1.24)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure | (1.25)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure | |
| Free cash flow | $m | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | (24.5)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$24.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-24, accession 0001193125-26-120690.Capital expenditure: $21.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure | not reported (Capital expenditure not reported) | (49.5)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$49.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-24, accession 0001193125-26-120690.Capital expenditure: $3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-24, accession 0001193125-26-120690.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 2026-06-30 | $49.7m | 7,614,836 | New+7,614,836 | |
| TPG GP A, LLC | 2026-06-30 | $44.9m | 6,877,580 | New+6,877,580 | |
| venBio Partners LLC | 2026-06-30 | $38.6m | 5,914,720 | New+5,914,720 | |
| Logos Global Management LP | 2026-06-30 | $35.4m | 5,425,000 | New+5,425,000 | |
| BlackRock, Inc. | 2026-06-30 | $34.4m | 5,272,017 | Added+4,832,657 | |
| FRANKLIN RESOURCES INC | 2026-06-30 | $32.3m | 4,953,220 | Added+584,027 | |
| Paradigm Biocapital Advisors LP | 2026-06-30 | $32.3m | 4,951,856 | New+4,951,856 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $27.0m | 4,140,812 | Added+1,936,098 | |
| Propel Bio Management, LLC | 2026-06-30 | $26.3m | 4,034,018 | Added+247,593 | |
| MARSHALL WACE, LLP | 2026-06-30 | $24.6m | 3,770,313 | Added+2,751,032 |
Recent filings
All 1,010 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0120:49 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-410781 |
| 2026-08-1420:09 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-352229 |
| 2026-08-1120:09 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344624 |
| 2026-08-1120:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344571 |
| 2026-07-0620:06 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-296174 |
| 2026-06-0820:06 ET | DEF 14A | Proxy statementPeriod 2026-06-08 | 0000949858-26-000006 |
| 2026-06-0212:51 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-252624 |
| 2026-05-1211:21 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-218177 |
| 2026-05-1211:20 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-218175 |
| 2026-04-3020:20 ET | 10-K/A | Annual report, amendedPeriod 2025-12-31 | 0001193125-26-197402 |
Latest annual report
Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 24, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 949858
- Tickers
- ACHV
- Exchange
- Nasdaq
- SIC code
- 2835 In Vitro & In Vivo Diagnostic Substances
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- ONCOGENEX PHARMACEUTICALS, INC. (to 2017-07-31); SONUS PHARMACEUTICALS INC (to 2008-08-07)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. Listed shows no prices and gives no investment advice.